Ferumoxytol as an MRI contrast agent has the advantage of long intravascular phase and strong transverse relaxivity, allowing high resolution depiction of abnormal vasculature and steady state blood volume (SS-CBV) mapping. In clinical studies it would be beneficial to use ferumoxytol as an immediate extension of standard of care gadolinium enhanced MRI, instead of imaging on two separate days. This study concludes that the 3D T2* weighted acquisition has substantial T1 weighting, while the 2D acquisition does not, therefore the latter one is preferable for ferumoxytol vascular imaging if gadolinium is on board.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords